S1PR1 and relapsing-remitting multiple sclerosis: With the approval of fingolimod (FTY720), a S1P1, 3–5 agonist, as a first oral medication for the treatment of RRMS patients, S1P receptors have attracted a greater degree of interest for their contribution in various disease conditions [52].